Purpose: To evaluate HER-2/neu-specific antibody immunity in patients with breast cancer, to determine the rate of occurrence of serum antibodies to HER-2/neu in patients with breast cancer, and to relate the presence of specific immunity to overexpression of HER-2/neu protein in primary tumor.
ER-2/NEU IS AN ONCOGENIC PROTEIN that is
overexpressed in 30% of invasive breast cancers and 60% to 80% of ductal carcinomas-in-situ (DCIS) comedo type. Overexpression of the HER-2/neu protein in a primary breast cancer may effect prognosis. Overexpression is associated with more aggressive disease and a poor prognosis in patients with positive lymph nodes. 2 However, the relationship between HER-2/neu protein overexpression and outcome is complex and overexpression is not always associated with aggressive disease. It has been established that overexpression is related to a favorable prognosis in patients with stage I breast cancer that contains inflammatory infiltrates. 3 A possible explanation for this finding is that the cellular infiltrates present in these tumors may represent an immune response directed against autologous cancer cells. This hypothesis has not yet been established.
Little is known concerning the immunogenicity of human breast cancer. Few studies have evaluated immunity to known and defined antigens and explored the role immunity plays in disease progression.
" ' It is known that some breast cancer patients have detectable antibody and T-cell immune responses to HER-2/neu. 6 9 However, the reported responses are described for only a few patients and are of low magnitude. In essence, these studies are individual case reports. No general assessment of immunity to HER-2/neu in cancer patients has been reported. The current study was designed to evaluate the presence and level of HER-2/neu-specific antibody immunity at the time of diagnosis in a population of breast cancer patients. The data establish that HER-2/neu-specific antiof 44 (20%) patients with HER-2/neu-positive tumors had HER-2/neu-specific antibodies, whereas three of 63 (5%) patients with HER-2/neu-negative tumors had antibodies (P = .03). The antibody responses could be substantial. Titers of greater than 1:5,000 were detected in five of 107 (5%).
Conclusion: The presence of HER-2/neu antibodies in breast cancer patients and the correlation with HER-2/ neu-positive cancer implies that immunity to HER-2/neu develops as a result of exposure of patients to HER-2/neu protein expressed by their own cancer. These findings should stimulate further studies to develop the detection of immunity to oncogenic proteins as tumor markers, as well as the development and testing of vaccine strategies to induce and augment immunity to HER-2/neu for the treatment of breast cancer or prevention of recurrent disease.
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body immunity can occur in many breast cancer patients and is not an isolated phenomenon. In addition, the presence of HER-2/neu-specific antibody correlates with HER-2/neu protein overexpression in the primary tumor, which strongly implies that tumor-specific immunity occurs as a direct result of HER-2/neu overexpression. Indeed, patients are immunized to the HER-2/neu protein expressed by their own tumor. Furthermore, the titer of HER-2/neu-specific antibody was high enough in some patients to predict that the antibody might have an effect on the tumor in some individuals. Further studies are needed to determine whether the high-titer antibody plays any role in cancer phenotype or progression.
METHODS

Patient Samples
With informed consent, serum was obtained at the time of diagnosis from 107 female breast cancer patients surgically treated at the Instituto Nazionale Tumori of Milan from 1990 to 1992, or at Ospedale Civile of Venice from 1991 to 1992. Stage was evaluated according to the postsurgical classification (pathologic tumor-nodemetastasis [TNM] stage) as reported by the International Union Against Cancer (UICC). Tissue and serum were collected at the time of the initial surgery in all patients who underwent surgical tumor resection. Patient selection was made on the basis of both serum and tissue availability for analysis. Tissue and sera were stored in aliquots at -80°C and -30°C, respectively, until used. All statistical analysis were calculated using the x 2 test with Yates correction.
Normal Blood Donors
Control sera were derived from normal donors who contributed blood products at the Puget Sound Blood Bank. Sera from 100 females and 100 males were aliquoted into 200-pL fractions and stored at -70°C. The age range of the control group was 25 to 65 years.
Tumor Immunostaining for Overexpression of the Her-2/neu Oncoprotein
Expression of HER-2/neu was determined by immunoperoxidase assay as described previously'°with the avidin-biotin-peroxidase complex (ABC) kit (Vector, Burlingham, CA). Expression was analyzed on paraffin-embedded or on frozen sections of the tumor specimens. Quality-control specimen staining showed superimposible results with both material (data not shown). Briefly, 5-/m formalinfixed paraffin sections and/or 3-to 5-Mm cold acetone-fixed cryosections were reacted with purified Ab3 monoclonal antibody at 2.5 pgl mL (Oncogene Science, Manhasset, NY). Tumors were considered positive for oncoprotein expression when strong membrane labeling was observed in more that 10% of the tumor cells of the invasive component.
Cell Lines
SKBR3 was used as a source of human HER-2/neu protein. SKBR3, a human breast cancer cell line, markedly overexpresses HER-2/neu protein (American Type Culture Collection, Rockville, MD), and was maintained in culture in 10% fetal bovine serum (FBS; Gemini Bioproducts, Inc, Calabasas, CA) and RPMI.
Preparation of Cell Lysates
HER-2/neu protein for enzyme-linked immunosorbent assay (ELISA) was obtained from lysates of SKBR3. Briefly, a lysis buffer that consisted of Tris base, sodium chloride, and Triton-X-100 (1%) pH 7.5 was prepared. The following protease inhibitors were added: aprotinin (I pg/mL), benzamidine (1 mmol/L), and phenylmethylsulfonyl fluoride (PMSF; I mmol/L). One milliliter of the lysis buffer was used to suspend 107 cells. The SKBR3 cells were vortexed until disrupted. After disruption, the cells were microfuged for 20 minutes. All procedures were performed on ice in a 4°C cold room. Supematant was removed from cell debris and stored in small aliquots at -70°C until used. Presence of human HER-2/neu in the lysates was documented by Western blot analysis.
DISIS ET AL
ELISA for the Detection of Human Her-2/neu-Specific Antibody Responses
Ninety-six-well Immulon 4 plates (Dynatech Laboratories, Chantilly, VA) were incubated overnight at 4°C with an immunoglobulin Gl k (IgGlk) murine monoclonal antibody directed against human Antigen specificity was confirmed by analyzing experimental sera for antibody responses to ovalbumin in an ELISA. In these analyses, plates were incubated overnight at 4°C with purified ovalbumin protein at a concentration of 10 g/mL in carbonate buffer alternated with rows of buffer alone. Antibody evaluation then proceeded as described earlier.
RESULTS
Patients with breast cancer have antibodies directed against the HER-2/neu oncogenic protein and the presence of antibody correlates with having breast cancer. Sera were obtained from 107 patients with breast cancer at the time of diagnosis and analyzed for the presence of human antibodies directed against the HER-2/neu oncoprotein. Antibodies at titers of 1:100 or greater were detected in 12 of 107 (11%) breast cancer patients compared with none of 200 (0%) normal controls (P = .0001) (Fig  1) . Thus, a HER-2/neu antibody titer -1:100 was detected only from cancer patients. However, low-titer anti- The presence of antibodies to HER-2/neu correlates with HER-2/neu protein overexpression in the patient's tumor and can be detected in early-stage patients. The HER-2/neu protein status of the primary breast cancers in these patients was evaluated by immunohistochemical staining. Endogenous HER-2/neu-specific antibody responses, titer -1:100, correlated with HER-2/neu protein overexpression in the tumor. Nine of 44 (20%) patients with HER-2/neu-positive tumors had HER-2/neu-specific antibodies, compared with three of 63 (5%) patients with HER-2/neu-negative tumors (P = .03) (Fig 1) . Analyzed according to stage, antibody was detected in nine of 39 (23%) patients with HER-2/neu-positive stage I or stage II disease versus three of 56 (5%) patients with HER-2/neu-negative stage I or stage II disease (P = .02) (Fig 2) . No patients with stage IV disease (n = 12) had HER-2/neu-specific antibodies; however, few appro- High-titer HER-2/neu antibodies can be detected in some early-stage patients. If antibody to HER-2/neu plays any role in vivo in breast cancer, the ability of antibody to function is likely to correlate with the presence of higher titer responses. Titers greater than 1:5,000 were detected in five of 107 patients (Fig 3) . All of the hightiter responses were observed in patients with early-stage disease. One of these patients had stage I cancer and the other four had stage II breast cancer. Too few patients with advanced-stage disease were evaluated to be able to correlate titer with stage. The antibody responses detected were specific for HER-2/neu. Responses to an irrelevant protein, ovalbumin, were not detected.
DISCUSSION
Previous studies established that some patients with breast cancer have preexistent antibody reactivity 6 ' 7 and T-cell reactivity 89 to HER-2/neu protein. For the most part, these studies described immunity in a few patients or a single patient. Moreover, responses were evaluated at random points in time. This is the first report of the detection of HER-2/neu-specific antibodies in a defined group of patients with breast cancer. The current studies establish that antibody reactivity correlates with the pres- ence of breast cancer. Furthermore, HER-2/neu-specific antibody responses correlate with HER-2/neu protein overexpression by the primary cancer and can be substantial, with titers greater than 1:5,000 detected in some patients with early-stage disease.
The detection of preexistent human antibody responses directed against the HER-2/neu protein in patients with breast cancer might prove to have important clinical ramifications for early diagnosis and therapy. Concerning possible therapeutic ramifications, the HER-2/neu protein is a growth factor receptor. HER-2/neu-specific monoclonal antibodies have been shown to have a cytostatic effect on cancer cell growth in vitrot 2 and can protect animals from developing neu-expressing tumors in vivo. ' 3 Recent studies have demonstrated the efficacy of infused humanized monoclonal antibody directed toward the HER-2/neu protein in the treatment of advanced-stage breast cancer in humans.' 4 An endogenous human antibody response may impart a positive therapeutic effect, similar to monoclonal antibodies directed toward the protein.
The presence of antibodies to HER-2/neu correlated significantly with the presence of breast cancer. While HER-2/neu antibodies were associated with HER-2/neu protein overexpression in the patients' primary tumor, particularly in early-stage patients, some patients with HER-2/neu-negative tumors had evidence of an antibody response. Clearly, women with HER-2/neu-overexpressing tumors can be immunized to the protein by virtue of its expression in their own cancer. The observation that HER-2/neu-specific antibodies can be identified in some women with HER-2/neu-negative breast cancer underlines the possibility of an active immunoselection for HER-2/neu-negative variants. The incidence of HER-2/neu protein overexpression is much higher in DCIS than in invasive breast carcinoma. Possibly, some women with undiagnosed HER-2/neu-overexpressing DCIS develop an immune response directed against HER-2/neu. If that immune response is effective, HER-2/neu-overexpressing cells will be eradicated, but immunity will persist. In other patients, the invasive cancer might escape as a HER-2/neu antigen-negative cancer. An immune response that results in escape of HER-2/neu-negative cancer theoretically might still be beneficial to the patient. HER-2/neu-negative cancers are less aggressive than those that overexpress the neu protein, and are associated with a more favorable prognosis, particularly in lymph node-positive disease. The validity of this theory can be tested only by the study of sera obtained from a large number patients with DCIS by following patients serially.
Concerning possible ramifications for early diagnosis, if antibody responses prove to occur at the in situ stage of breast cancer, detection of antibody may be an early indicator of exposure to the malignant phenotype. In addition, for patients in remission, antibody responses might also prove to be sensitive assays useful for predicting relapse at a minimal disease state. As tumor recurs, exposure of the immune system to increased levels of HER-2/neu antigen might stimulate an increasing titer antibody response. Increasing titer of antibody to HER-2/neu could serve as an early harbinger of relapse. However, of note, no patients with advanced-stage disease had detectable HER-2/neuspecific antibodies. Although the number of patients available for analysis is small, this raises the possibility of native antibody interaction with circulating ECD. The extracellular domain of HER-2/neu has been shown to circulate in the sera of advanced-stage patients.'
5 Antigen-specific antibodies that complex with circulating antigen may not allow accurate quantitation of either HER-2/neu specific antibodies or circulating antigen in patients with bulky disease. 6 Substantial antibody responses of greater than 1:5,000 were found in five of 107 patients, all with early-stage disease. The obvious question is whether the high-titer antibody responses translate into an improved outcome. The presence of high-titer antibody in early-stage disease allows room for speculation that the development of immunity in response to a HER-2/neu-positive cancer might have an impact on the growth and metastasis of that cancer. However, too few patients were available for analysis and the length of follow-up evaluation was too short to allow determination of outcome in relation to immunity. Determination of the influence of preexistent immunity on outcome will require study of a larger num- 
HER-2/neu ANTIBODY IN EARLY-STAGE BREAST CANCER PATIENTS
ber of patients with defined clinical characteristics treated in a similar fashion. HER-2/neu overexpression correlates with an improved prognosis in patients with early-stage HER-2/neu-positive cancers when lymphoplasmacytic infiltration is present.
3' ' 6 '7 These patients should be evaluated to determine whether the lymphoplasmacytic infiltration correlates with immunity to HER-2/neu. Many treatment strategies have been designed to target the HER-2/neu protein. Promising interventions in current clinical trials center around giving a breast cancer patient an immune response against HER-2/neu via infusions of different forms of monoclonal or bispecific antibodies.' 4 8 There are several limitations to antibody therapy, including the generation of immunity to the antibody construct, the short half-life of infused antibodies, and the inability of antibodies to penetrate solid tumors. The current study provides evidence that women with HER-2/neu-overexpressing tumors are immunized to the protein by virtue of its expression in their own cancer and gives credence to speculation that it will be possible to induce substantial immunity against HER-2/neu by immunization boosting with HER-2/neu vaccines. Generating a vigorous endogenous HER-2/neu-specific antibody response will circumvent many of the problems observed with monoclonal antibody therapies. In addition, the generation of an autologous response offers the theoretic advantage of resultant long-term immunologic memory that may confer lifelong protection against the recurrence of HER-2/neu-mediated malignancy.
